These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22702634)

  • 1. Novel strategies in drug discovery of the calcium-sensing receptor based on biased signaling.
    Thomsen AR; Smajilovic S; Bräuner-Osborne H
    Curr Drug Targets; 2012 Sep; 13(10):1324-35. PubMed ID: 22702634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent updates on the calcium-sensing receptor as a drug target.
    Trivedi R; Mithal A; Chattopadhyay N
    Curr Med Chem; 2008; 15(2):178-86. PubMed ID: 18220773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
    Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD
    J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strontium is a biased agonist of the calcium-sensing receptor in rat medullary thyroid carcinoma 6-23 cells.
    Thomsen AR; Worm J; Jacobsen SE; Stahlhut M; Latta M; Bräuner-Osborne H
    J Pharmacol Exp Ther; 2012 Dec; 343(3):638-49. PubMed ID: 22942242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The calcium-sensing receptor has only a parathyroid hormone-dependent role in the acute response of renal phosphate transporters to phosphate intake.
    Daryadel A; Küng CJ; Haykir B; Sabrautzki S; de Angelis MH; Hernando N; Rubio-Aliaga I; Wagner CA
    Am J Physiol Renal Physiol; 2024 May; 326(5):F792-F801. PubMed ID: 38545651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Calcimimetics].
    Messa P; Como G; Brezzi B
    G Ital Nefrol; 2006; 23(1):12-21. PubMed ID: 16521071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.
    Quarles LD
    Kidney Int Suppl; 2005 Jul; (96):S24-8. PubMed ID: 15954947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion.
    Kantham L; Quinn SJ; Egbuna OI; Baxi K; Butters R; Pang JL; Pollak MR; Goltzman D; Brown EM
    Am J Physiol Endocrinol Metab; 2009 Oct; 297(4):E915-23. PubMed ID: 19797241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion.
    Centeno PP; Herberger A; Mun HC; Tu C; Nemeth EF; Chang W; Conigrave AD; Ward DT
    Nat Commun; 2019 Oct; 10(1):4693. PubMed ID: 31619668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues.
    Quarles LD
    Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):349-55. PubMed ID: 12815330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium-sensing receptors.
    Goodman WG
    Semin Nephrol; 2004 Jan; 24(1):17-24. PubMed ID: 14730506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium-sensing receptor expression and signalling in human parathyroid adenomas and primary hyperplasia.
    Corbetta S; Mantovani G; Lania A; Borgato S; Vicentini L; Beretta E; Faglia G; Di Blasio AM; Spada A
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):339-48. PubMed ID: 10718832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etelcalcetide decreases the PTH-calcium setpoint without changing maximum and minimum PTH secretion in mice with primary hyperparathyroidism.
    Hayashi N; Imanishi Y; Hirakawa T; Kobayashi I; Tateishi T; Miyaoka D; Nagata Y; Mori K; Morioka T; Inoue A; Harada K; Inaba M; Emoto M
    J Bone Miner Metab; 2021 May; 39(3):430-438. PubMed ID: 33196900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Basic and clinical aspects of calcimimetics. Structure and function of calcium-sensing receptor].
    Fukumoto S
    Clin Calcium; 2008 Jan; 18(1):32-6. PubMed ID: 18175869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinacalcet in hyperfunctioning parathyroid diseases.
    Imanishi Y; Inaba M; Kawata T; Nishizawa Y
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S7-S11. PubMed ID: 19765257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics.
    Goodman WG; Quarles LD
    Kidney Int; 2008 Aug; 74(3):276-88. PubMed ID: 17568787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.
    Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y
    Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the calcium-sensing receptor in parathyroid gland physiology.
    Chen RA; Goodman WG
    Am J Physiol Renal Physiol; 2004 Jun; 286(6):F1005-11. PubMed ID: 15130894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
    Nagano N; Nemeth EF
    J Pharmacol Sci; 2005 Mar; 97(3):355-60. PubMed ID: 15781990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.